Investigational drug · Phase 3
ibuzatrelvir
Also called: PF-07817883
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for COVID-19 SARS-CoV-2 Infection, COVID-19 Infection.
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
6
Any phase or sponsor naming "ibuzatrelvir"
First trial start
2024
Dec 8, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ibuzatrelvir", any sponsor or status.
Conditions studied
As listed on its trial records.
- COVID-19 SARS-CoV-2 Infection
- COVID-19 Infection
Approved drugs for the same conditions: COVID-19 · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "ibuzatrelvir" as an intervention, largest first.
- A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe DiseasePivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT06679140 · 2,330 participants (planned) · Start Dec 8, 2024 · Primary completion Oct 1, 2027
Drug: ibuzatrelvir; placebo · For: COVID-19 SARS-CoV-2 Infection
Sites: Huntsville, Alabama; Little Rock, Arkansas; Bakersfield, California · 256 sites in all
- A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely ImmunocompromisedPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07013474 · 300 participants (planned) · Start Jul 14, 2025 · Primary completion Sep 28, 2027
Drug: ibuzatrelvir; remdesivir and 2 more · For: COVID-19 Infection
Sites: Canoga Park, California; Granada Hills, California; La Jolla, California · 159 sites in all
PfizerPfizer (PFE)
NCT06693518 · 20 participants · Start Nov 22, 2024 · Primary completion Jan 15, 2025
Drug: Treatment B; Treatment A · For: SARS-CoV-2 Infections
Sites: Brussels, Belgium
PfizerPfizer (PFE)
NCT07552779 · 17 participants · Start Apr 13, 2026 · Primary completion Jun 3, 2026
Drug: Ibuzatrelvir co-process API film coated tablet; Ibuzatrelvir filmcoated tablet · For: Coronavirus Disease 2019; Coronavirus Disease 2019 (COVID-19); COVID-19 (Coronavirus Disease 2019) and 8 more
Sites: Brussels, Belgium
PfizerPfizer (PFE)
NCT06646042 · 12 participants · Start Oct 28, 2024 · Primary completion Jan 17, 2025
Drug: ibuzatrelvir; carbamazepine ER · For: Healthy
Sites: New Haven, Connecticut
PfizerPfizer (PFE)
NCT07235137 · 12 participants · Start Oct 16, 2025 · Primary completion Nov 21, 2025
Drug: Ibuzatrelvir · For: Healthy Participant
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- A Multipart Phase 1 Study to Assess Safety and Pharmacokinetics of Ibuzatrelvir in Healthy Participants and Dose Selection for a Dose-Ranging Study.
Singh RSP, Toussi SS, Hackman F, et al. · Clin Transl Sci 2026
- Inhibitory effects and structural analysis of drug candidate PF-07817883 against coronaviral main proteases (Mpro) and SARS-CoV-2 Mpro mutants.
Zhao Z, Zhou X, Jiang H, et al. · J Struct Biol X 2026
- Cross-resistance patterns in SARS-CoV-2 against 3CL protease inhibitors.
Chithelen J, Lovett DH, Wang K, et al. · Nat Commun 2026
- Analysis of ibuzatrelvir's activity against SARS-CoV-2 circulating variants and in vitro resistance mutations.
Yurgelonis I, Rai DK, Li Z, et al. · Antiviral Res 2026
- Ibuzatrelvir potently reduced viral RNA levels despite a high rate of anti-S seropositivity: a post hoc analysis of serology of the phase 2b study.
Kim JH, Knutson A, Smith J, et al. · Sci Rep 2026
- Characterization of the Cross-Resistance of SARS-CoVߛ2 Main Protease Inhibitors, Ibuzatrelvir, Ensitrelvir, and Nirmatrelvir.
Tan H, Chi X, Deng X, et al. · ACS Pharmacol Transl Sci 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Pfizer.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.